Market Dynamics
The pharmacovigilance market in the U.K. has grown in recent years due to the increasing demand for medication safety monitoring, triggering regulatory agencies to maintain a close watch on the safety and efficacy of marketed drugs. The increasing population in the country and the increasing purchase of prescription drugs is also expected to increase the demand for specialists who monitor the safety and efficacy of drugs. Currently, the U.K. pharmacovigilance market consists of several local and multinational companies that provide drug safety and efficacy services such as adverse events reporting, pharmacovigilance compliance assistance, risk management, pharmacovigilance training, and medical writing services. Furthermore, the growing number of clinical trials conducted in the U.K. also drives the demand for pharmacovigilance services, as it increases the workload and complexity of drug safety monitoring. The UK government has established policies to support the pharmacovigilance market. These include the introduction of Good Clinical Practices (GCP), Medicines Research and Regulation (MRR), and Medicines Regulatory Framework (MRF). The pharma companies in the U.K. must abide by the GCP, MRR and MRF guidelines while researching and marketing drugs.
Additionally, the plans to foster the development of intelligent models to make pharmacovigilance more efficient and automated would help the industry cope up with the increased demand. Advancement in cross-border research data sharing has also enabled more efficient monitoring of safety and efficacy of drugs. Companies are collaborating across borders to enhance their Pharmacovigilance capabilities and monitor safety across the globe. Companies such as Palleon Pharma, Pliva Healthcare, and Broadley Pharma have a larger presence in the U.K. pharmacovigilance market and are expected to be the leading players in the industry. In conclusion, the U.K. pharmacovigilance market is expected to grow in the coming years due to the increasing demand for medication safety monitoring, triggering regulatory agencies to maintain a close watch on the safety and efficacy of marketed drugs. Moreover, the government policies to support the pharmacovigilance market, emerging technologies to automate the pharmacovigilance process, and cross-border collaborations have also played a role in driving the demand.
